source
- Epicrispr reports encouraging early data from EPI-321 in 12 patients with FSHDEpicrispr Biotechnologies released updated data on its epigenetic editing therapy EPI-321 aimed at treating facioscapulohumeral muscular dystrophy (FSHD). The company has now dosed twelve particip…
- CSL agrees $355M upfront deal to co-develop Alentis anti-fibrosis drug for kidney and liverCSL, an Australian drugmaker, announced a partnership with Alentis Therapeutics that includes a $355 million upfront payment. Under the agreement, CSL will co-develop Alentis's anti-fibrosis candi…